Discoid lupus erythematosus
ICD-10 L93.0 · ICD-11 EB51.0

Treatment of Discoid Lupus Erythematosus with Severe or Widespread Skin Lesions

This protocol addresses the management of discoid lupus erythematosus in patients presenting with severe or widespread skin involvement, particularly where there is a risk of scarring or progression to systemic disease.

Clinical Scenario

Severe or widespread skin lesions of discoid lupus erythematosus — or presentation with a risk of scarring or development of systemic disease — in patients who are not pregnant and not breastfeeding.

Treatment Approach

Antimalarials are central to long-term systemic management in this setting. The protocol incorporates Methotrexate in combination with antimalarials for patients requiring additional disease control — the complete regimen, including route and sequencing, is available in the full structured protocol.

Instant Access to Structured Evidence-Based Regimens
References
  1. We recommend antimalarials as first-line and long-term systemic treatment in all CLE patients with severe or widespread skin lesions, in particular in patients with the risk of scarring and development of systemic disease.
  2. In severe or widespread active CLE lesions, systemic corticosteroids are recommended as first-line treatment in addition to antimalarials.
  3. We recommend MTX up to 20 mg per week as a second-line treatment, primarily in SCLE patients, preferably subcutaneously and in addition to antimalarials.
View source ↗